4 minute read
Jan. 28, 2023
A "Bow-Tie" Spirocyclopropyl LRRK2 Inhibitor from Merck
compound 25
kinome selective, CNS-penetrant, type I LRRK2 inhibitor in vivo activity in preclinical PK/PD model scaffold hopping + opt. of MLi-2 J. Med. Chem., December 7, 2022 Merck & Co., Boston, MA & Kenilworth, NJ
Reviewer:
Loading...
